Dami completed his bachelor’s degree in Cell and Molecular Biology with a minor in Psychology at Northeastern University. He studied the modification of the promoter region of the pili of A. baumannii and its effects on biofilm expression.

Dami is the lead clinical research coordinator for cAPPricorn-1, a new treatment trial sponsored by Alnylam Pharmaceuticals that aims to reduce the buildup of amyloid-beta by decreasing the production of amyloid precursor protein in patients with CAA. He is also involved in projects aiming to assess secondary tissue injury related to hemorrhage in CAA mouse models.

Outside of work, Dami likes to go hiking, kayaking, and play soccer.